Besides, treatment with the more bioavailable CARM1 inhibitor EZM2302 reduced tumor volume of p300MUT DLBCL cells in xenograft models, which was highly synergetic with p300/CBP inhibitors [167]. This evidence concerns the gene EP300 and diffuse large B-cell lymphoma.